Thermo Fisher Scientific Inc. announced it will expand its response to the COVID-19 pandemic by developing a total antibodies test in collaboration with WuXi Diagnostics and Mayo Clinic. The new test is the result of ongoing collaboration between all three organizations, including clinical evaluation and support from Mayo Clinic. Thermo Fisher will seek US FDA Emergency Use Authorization (EUA) and international regulatory authorizations for the test over the next few weeks.
"Rapidly expanding access to high-quality testing requires bold collaborations across the laboratory industry,” says Gianrico Farrugia, MD, chief executive officer and president of Mayo Clinic. "This marks a significant milestone in our national testing response to COVID-19 and was made possible by bringing together the commercialization capabilities of Thermo Fisher Scientific, testing development abilities of WuXi Diagnostics, and clinical and laboratory expertise of Mayo Clinic physicians and scientists."
For the latest updates on the COVID-19 pandemic, check the Centers for Disease Control and Prevention website. For more information and COVID-19 coverage, go to the Mayo Clinic News Network and mayoclinic.org.
